DCE-MRI for Pancreatic Cancer

This trial aims to evaluate how effectively a special type of MRI scan, called dynamic contrast enhanced MRI (DCE-MRI), assesses the response of pancreatic cancer treatments. It targets individuals with a type of pancreatic cancer that may be surgically removable with appropriate treatment. Participants will receive standard treatments, including chemotherapy drugs such as Fluorouracil, Gemcitabine, Irinotecan, Nab-paclitaxel, and Oxaliplatin. The DCE-MRI will assist doctors in understanding the cancer's response. Ideal candidates have pancreatic cancer affecting nearby arteries or veins but no distant disease spread. As a Phase 1, Phase 2 trial, this research focuses on understanding the treatment's effects in people and measuring its effectiveness in an initial, smaller group.

Research has shown that the treatments in this study—Fluorouracil, Gemcitabine, Irinotecan, Nab-paclitaxel, and Oxaliplatin—have varying safety levels based on past studies.

Fluorouracil has been widely used in studies for pancreatic cancer. It can cause side effects like reduced bone marrow activity, tiredness, and vomiting. However, the FDA has approved it for several cancers, including pancreatic cancer, indicating it is generally safe under medical supervision.

Gemcitabine is another well-studied drug. Research indicates that its side effects are usually moderate and manageable. It is often used with Nab-paclitaxel, a combination approved by the FDA for pancreatic cancer, suggesting it is safe when used correctly.

Irinotecan has been part of cancer treatments for some time. It may cause side effects like diarrhea and a low white blood cell count, but its FDA approval shows that its benefits in treating cancers are well-recognized.

Nab-paclitaxel, commonly used with Gemcitabine, generally has manageable side effects with proper monitoring. This combination has been shown to increase survival in pancreatic cancer patients, indicating its effectiveness and relative safety.

Oxaliplatin is often used in combination therapies. It is generally considered tolerable, with side effects that can be effectively controlled.

Researchers are excited about this trial because it uses DCE-MRI, a dynamic contrast-enhanced imaging technique, to better understand how pancreatic cancer responds to treatment. Unlike traditional imaging methods, DCE-MRI provides detailed insights into tumor blood flow and vascular characteristics, potentially leading to more personalized treatment strategies. By combining this advanced imaging with standard chemotherapy options like gemcitabine, nab-paclitaxel, and others, researchers hope to improve the precision and effectiveness of pancreatic cancer therapies.

Research has shown that combining the drugs fluorouracil and irinotecan, often with leucovorin, can extend the lives of patients with advanced pancreatic cancer. In this trial, participants may receive this combination as part of their standard care. Studies have also found that using gemcitabine with nab-paclitaxel significantly improves survival rates compared to gemcitabine alone, making it another treatment option in this trial. Additionally, oxaliplatin, when combined with other drugs like gemcitabine, has effectively treated advanced pancreatic cancer, benefiting many patients. These treatments typically aim to shrink tumors or slow their growth, improving the chances of successful surgery for patients with pancreatic cancer that is nearly but not quite removable.⁶⁷⁸⁹¹⁰